DUBLIN – Vasopharm GmbH raised €20 million (US$21.7 million) in a new funding round to take its lead molecule, VAS203, into a European phase III registration trial in traumatic brain injury (TBI). The study is due to begin in the coming months and is due to read out in 2019.